BiotechTube

Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet

Phase 2/3Active
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Abdominal Aortic Aneurysm

Conditions

Abdominal Aortic Aneurysm

Trial Timeline

Sep 26, 2018 → May 1, 2024

NCT ID
NCT03507413

About Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet

Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet is a phase 2/3 stage product being developed by Merck for Abdominal Aortic Aneurysm. The current trial status is active. This product is registered under clinical trial identifier NCT03507413. Target conditions include Abdominal Aortic Aneurysm.

What happened to similar drugs?

6 of 20 similar drugs in Abdominal Aortic Aneurysm were approved

Approved (6) Terminated (1) Active (14)
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalinPfizerApproved
✅Tigecycline + Imipenem/cilastatinPfizerApproved
✅tigecyclinePfizerApproved
✅Fibrinogen concentrate + Fresh Frozen PlasmaCSLApproved
✅Sevoflurane + propofol + remifentanilBaxterApproved
🔄PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
15
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03507413Phase 2/3Active

Competing Products

20 competing products in Abdominal Aortic Aneurysm

See all competitors
ProductCompanyStageHype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3
36
HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
35
Ticagrelor + PlaceboAstraZenecaPhase 2
35
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactamMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3
40
CXA-201 and metronidazole + MeropenemMerckPhase 3
40
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 WeeksMerckPhase 3
40
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
ACZ885 + PlaceboNovartisPhase 2
27
Evolocumab + PlaceboAmgenPhase 1
36
tigecyclinePfizerPhase 3
40
recombinant human growth hormonePfizerPhase 3
40
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalinPfizerApproved
35
Ceftazidime-avibactam + metronidazole + MeropenemPfizerPhase 3
40